This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): tarenflurbil, R-flurbiprofen, MPC-7869, E-7869
Description: Flurizan is the pure R-enantiomer form of flurbiprofen - an NSAID (non-steroidal anti-inflammatory drug) with 25 years of clinical experience behind it. Unlike NSAIDs, however, Flurizan is not an inhibitor of cyclooxygenase enzymes (COX-1 and COX-2). Flurizan is the first in a new class of drug candidates known as selective amyloid beta 42 lowering agents (SALAs). Flurizan is the first to receive the new word stem, --flurbil, and will now be known generically as tarenflurbil.
The amyloid hypothesis states that Alzheimer's disease is initiated by the accumulation of toxic amyloid beta (Aß42) which causes cell death in the brain and initiates the formation of amyloid plaques. In contrast, shorter forms of the amyloid peptide are less toxic and do not initiate plaque deposits. Flurizan has been demonstrated by Myriad scientists and their collaborators to be a Selective Aß42 Lowering Agent (SALA) in cultured human cells and in animal models. The data generated to date suggest that Flurizan modulates, rather than inhibits, gamma-secretase to preferentially reduce the generation of the longer toxic Aß42 peptide without much effect on Aß40. As a Selective Aß42-lowering Agent, Flurizan does this without affecting the processing of other essential gamma-secretase substrates.
Deal Structure: In May 2008, Myriad Genetics announced the selection of H. Lundbeck A/S for European commercialization of Flurizan for the treatment of Alzheimer's disease.
Myriad and Lundbeck have entered into a European commercialization agreement under which Lundbeck will have rights to market and sell Flurizan in the European Union and several associated non-EU countries and will manage the regulatory process. Lundbeck has agreed to pay Myriad an initial $100 million and will pay up to $250 million in connection with regulatory approvals. Furthermore, Lundbeck has agreed to pay commercialization milestones and will purchase bulk pharmaceutical material from Myriad. Lundbeck has also agreed to pay escalating royalties of 20 - 39% on sales, less the amount paid for the bulk drug.
In October 2008, Myriad Genetics announced that its Board of Directors has authorized management to proceed with preparations to spin off its research and drug development businesses from its molecular diagnostics...See full deal structure in Biomedtracker
Partners: H. Lundbeck A/S
Additional information available to subscribers only: